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ARTICLE
Human antibodies targeting Zika virus NS1 provide
protection against disease in a mouse model
Mark J. Bailey 1,2, James Duehr1,2, Harrison Dulin3, Felix Broecker1, Julia A. Brown1,2, Fortuna O. Arumemi4,
Maria C. Bermúdez González1,5, Victor H. Leyva-Grado1, Matthew J. Evans1, Viviana Simon1,5,6, Jean K. Lim1,
Florian Krammer 1, Rong Hai3, Peter Palese1,7 & Gene S. Tan4,8
Zika virus is a mosquito-borne ﬂavivirus closely related to dengue virus that can cause severe
disease in humans, including microcephaly in newborns and Guillain-Barré syndrome in
adults. Speciﬁc treatments and vaccines for Zika virus are not currently available. Here, we
isolate and characterize four monoclonal antibodies (mAbs) from an infected patient that
target the non-structural protein NS1. We show that while these antibodies are non-neu-
tralizing, NS1-speciﬁc mAbs can engage FcγR without inducing antibody dependent
enhancement (ADE) of infection in vitro. Moreover, we demonstrate that mAb AA12 has
protective efﬁcacy against lethal challenges of African and Asian lineage strains of Zika virus
in Stat2–/– mice. Protection is Fc-dependent, as a mutated antibody unable to activate known
Fc effector functions or complement is not protective in vivo. This study highlights the
importance of the ZIKV NS1 protein as a potential vaccine antigen.
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Zika virus (ZIKV) is an arthropod-borne ﬂavivirus closelyrelated to dengue, yellow fever and West Nile viruses,which has caused an emerging epidemic in the Americas,
the Caribbean, and the Paciﬁc regions. While ZIKV is spread
primarily through the bite of an infected Aedes species mosquito,
cases of sexual transmission have also been reported1,2. ZIKV
infection is associated with severe illness in humans including
microcephaly and birth defects in newborns3–5 and Guillain-
Barré syndrome in adults6,7. Consequently, ZIKV infection poses
signiﬁcant threats to global health.
To understand the molecular determinants of immunity to
ZIKV infection, several groups have isolated monoclonal anti-
bodies (mAbs) from patients infected with ZIKV8–12. These
studies have revealed important antigenic sites on the envelope
(E) protein required for virus neutralization. Quaternary epitopes
such as the “envelope dimer epitope”, which are dependent on the
native dimeric assembly of the E protein, are promising vaccine
and therapeutic targets, as mAbs generated against these sites
tend to be potently neutralizing10. However, one chief concern in
the development of ﬂavivirus vaccines targeting the E protein is
the phenomenon of antibody-dependent enhancement of disease
(ADE). This occurs when viral replication is enhanced by pre-
existing antibodies that opsonize but do not fully neutralize the
virion resulting in enhanced uptake of the virion-antibody
complex by FcγR-bearing target cells. The virus is then able to
replicate in these cells, increasing the severity of disease13.
Though there is no epidemiologic evidence that Zika virus can
cause ADE in humans, studies have shown ZIKV-induced
monoclonal antibodies targeting the E protein can enhance
infection of ZIKV or DENV in vitro and induce mortality in
DENV-infected mice8. Additionally, passive transfer of DENV or
WNV immune plasma to immunocompromised mice has resul-
ted in more severe disease progression upon ZIKV infection
in vivo14. Consequently, ADE may limit the therapeutic appli-
cation of E protein-speciﬁc antibodies and vaccines against Zika
virus.
Other viral proteins including non-structural 1 (NS1) protein
have emerged as promising targets as antibodies that do not bind
the virion are unlikely to enhance disease. In a recent study of
four patients infected by ZIKV, 34.4% of virus-speciﬁc mAbs
target the NS1 protein8. This immunogenic glycoprotein plays an
essential role in viral RNA replication and immune evasion. The
NS1 protein is initially translated as a monomer, becomes gly-
cosylated in the ER and subsequently forms a dimer that can
potentially trafﬁc to multiple distinct locations within the cell15.
The NS1 protein of many ﬂaviviruses is known to associate with
the viral replication complex on the surface of the endoplasmic
reticulum membrane, associate with the plasma membrane by a
glycosylphosphatidylinositol linker, exit cells to form a lipophilic
hexamer, and potentially bind to uninfected cells via glycosami-
noglycan interactions16.
Protective antibodies against viral pathogens are able to
protect via multiple mechanisms: neutralization, Fcγ-receptor
mediated viral clearance, and complement-dependent cytotoxi-
city (CDC)17. Antibodies against the NS1 protein were shown to
be protective against a number of different ﬂavivirus species. In
Japanese encephalitis virus, NS1-speciﬁc antibodies were found to
reduce viral output from infected cells18. Yellow fever virus NS1
fragments were used as a vaccine and immunized mice had
reduced neurovirulence upon viral challenge19. Later, NS1-
speciﬁc antibodies were found to protect against yellow fever
encephalitis in mice20. Additionally, mAbs targeting the yellow
fever virus NS1 protein protected monkeys against lethal chal-
lenge by invoking Fcγ-mediated effector functions20–22. Other
work has shown that mAbs against West Nile virus NS1 protein
prevent lethal infection in mice through Fcγ-receptor mediated
phagocytosis as well as an undetermined Fc-independent
mechanism23,24. The dengue virus NS1 protein has been exten-
sively studied in the context of antiviral immunity. Successful
passive protection studies were performed in mice with NS1-
speciﬁc monoclonal antibodies as well as protein and DNA
plasmid-based vaccines25–30. Recently, dengue virus NS1 protein
was shown to induce disruption of endothelial barriers in mice,
which can also be prevented by vaccination with the NS1 pro-
tein31. Finally, an NS1-based vaccine for Zika virus was suc-
cessfully tested in a mouse challenge model, proving that NS1-
mediated immunity alone is sufﬁcient for a protective vaccine32.
These studies in many related ﬂaviviruses suggest mAbs against
the ZIKV NS1 protein are likely protective. In our work, we plan
to determine if NS1-speciﬁc mAbs can provide protection in a
murine model and whether this protection relies upon Fcγ-
receptor effector functions.
Using a well-established protocol for the generation of fully
human mAbs33, we isolate ZIKV speciﬁc mAbs from the plas-
mablast compartment of a patient recently infected by ZIKV. The
variable regions of the heavy and light chains of isolated plas-
mablasts are then sequenced, cloned, and recombinantly
expressed. Here, we report the characteristics of four NS1-speciﬁc
antibodies found in an individual with symptomatic ZIKV
infection. Our data demonstrate that while NS1-speciﬁc mAbs do
not neutralize virus in vitro, they can confer FcγR-mediated
protection in vivo in a murine challenge model, which highlights
the importance of NS1 epitopes in vaccine development.
Results
ZIKV NS1 speciﬁc antibodies are induced in humans. To
investigate the antibody response to ZIKV infection, we obtained
plasma and isolated peripheral blood mononuclear cells (PBMCs)
from a patient who was infected with ZIKV while traveling in
Central America. The patient was likely not pre-exposed to
dengue based on history and past travel. Blood was collected ten
days after the patient tested positive for ZIKV RNA by RT-PCR.
We adapted a published protocol to isolate Zika virus-speciﬁc
mAbs from the plasmablast compartment of the infected
patient33,34.
Following single cell sorting of B cells, the variable regions of
the immunoglobulins were sequenced, cloned into a human IgG1
expression vector, and subsequently expressed in HEK 293F cells
as previously described33,34. The mAbs were then initially
screened for reactivity to ZIKV-infected Vero cells by immuno-
ﬂuorescence. Vero cells were infected with one of two strains of
Zika virus: either the African lineage MR766 which was isolated
in Uganda from a rhesus macaque in 1947 and subsequently
passaged in mice, or the Asian lineage PRVABC59, which was
isolated in Puerto Rico from a human patient in 2015 and is
representative of the current circulating strain. Additionally, we
tested a DENV-3 isolate from the Philippines to determine if our
antibodies cross-reacted with other ﬂaviviruses. We found that
three of the mAbs (AA12, EB9, and GB5) bound cells infected by
both MR766 and PRVABC59 and one antibody (FC12) that
bound cells infected by only PRVABC59 (Fig. 1a). None of our
antibodies cross-reacted with DENV-3 infected cells. We next
tested whether our antibodies bound by enzyme-linked immu-
nosorbent assay (ELISA) to recombinant NS1 protein (Fig. 1b, c).
We expressed and puriﬁed NS1 from both MR766 and
PRVABC59 strains of ZIKV. As expected, three antibodies bound
NS1 (AA12, EB9, and GB5) from both strains of ZIKV while
FC12 only bound NS1 from the recent PRVABC59 ZIKV isolate.
All mAbs were originally found to be of the IgG1 isotype and
carried a low number of somatic mutations (Table 1). Neutraliza-
tion activity was examined by microneutralization assays and
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-07008-0
2 NATURE COMMUNICATIONS |          (2018) 9:4560 | DOI: 10.1038/s41467-018-07008-0 | www.nature.com/naturecommunications
none of the NS1-speciﬁc mAbs exhibited neutralization activity
against either PRVABC59 or MR766 (Table 1). The binding
afﬁnities of each antibody to PRVABC59 and MR766 were then
determined using biolayer interferometry (Supplementary
Table 1). We found that the binding constants using biolayer
interferometry (Supplementary Table 1) were consistent with
observed ELISA data (Fig. 1b, c). As expected, FC12 only bound
NS1 from the recent PRVABC59 ZIKV isolate while AA12, GB5
and EB9 both bound potently to PRVABC59 or MR766.
NS1 speciﬁc mAbs activate Fc mediated effector functions. We
next evaluated the ability of NS1-speciﬁc mAbs to engage in Fcγ-
mediated effector functions. To model the activation of ADCC,
we used a genetically modiﬁed Jurkat cell line expressing human
FcγRIIIa and a luciferase reporter under a nuclear factor of
activated T-cells (NFAT) promoter as a surrogate to examine the
ability of these mAbs to engage and then activate Fcγ-mediated
effector functions. First, we infected Vero cells with either MR766
or PRVABC59 ZIKV. Next, we added NS1-speciﬁc mAbs at
concentrations ranging from 10 to 0.002 μg per mL. Consistent
with our earlier ELISA results, three mAbs (AA12, EB9, and GB5)
induced effector functions on both MR766 and PRVABC59 ZIKV
infected cells and one antibody (FC12) induced effector functions
only on PRVABC59 ZIKV (Fig. 2a, b).
Next, we determined whether transfection of NS1 is sufﬁcient
to activate Fc-FcγR effector functions by transfecting HEK
293T cells with an expression (pCAGGS) plasmid expressing
NS1 from either MR766 or PRVABC59 ZIKV. After incubation
with the same mAbs at the same concentrations, we found only
two of our mAbs (AA12 and EB9) induced effector functions on
both MR766 and PRVABC59 ZIKV transfected cells while the
remaining two antibodies induced effector functions on cells
transfected by NS1 from PRVABC59 ZIKV (Fig. 2c, d). The
discrepancy observed in antibody GB5 may be due to a limited
transfection efﬁciency of NS1 compared to NS1 being expressed
from infected cells. Alternatively, the conformation of transfected
NS1 from the PRVABC59 ZIKV isolate may limit the GB5
epitope as compared to the NS1 protein expressed by infected
cells. Nevertheless, we can conclude that the surface NS1 protein
in the absence of viral infection is sufﬁcient to activate Fcγ-
mediated effector functions induced by NS1-speciﬁc mAbs.
Lastly, we demonstrate that NS1-speciﬁc mAbs can direct the
activation of human primary NK cells. Here, we infected Vero
cells with PRVABC59 ZIKV at an MOI of 0.5. At 48 h post-
infection, dilutions of NS1-speciﬁc IgG1 mAbs, an irrelevant
mAb, or no mAb (starting at 20 µg per mL) in combination with
isolated primary human NK cells were incubated with the ZIKV-
infected Vero cells. After three hours, activation of NK cells was
measured as percent of CD56+ cells expressing CD107a. As
shown in Supplementary Figure 1, all NS1-speciﬁc mAbs can
measurably activate CD107a expression of NK cells from two
donors, ranging from 32 to 18% at 20 µg per mL. Of note,
CD107a expression between the irrelevant IgG and baseline
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Fig. 1 Human ZIKV speciﬁc-antibodies bind to both MR766 and PRVABC59 NS1 proteins. a Vero cells were infected with the indicated viruses at an MOI of
1 for 24 h. The cells were ﬁxed with 0.5% paraformaldehyde and blocked with 5% non-fat milk. MAbs AA12, FC12, EB9, and GB5 were used at a
concentration of 5 μg per mL and an anti-human antibody conjugated to Alexa Fluor 488 was used as a secondary antibody. The murine pan-ﬂavivirus mAb
4G2 was used as a positive control and an anti-mouse antibody conjugated to Alexa Fluor 488 was used as a secondary antibody. Cells stained with mAb
4G2 were ﬁxed and permeabilized using 80% acetone. b, c ELISA assays were performed using recombinant NS1 protein from either MR766 or PRVABC59
viruses to assess the binding activity of mAbs AA12, FC12, EB9, and GB5. ELISAs were performed in duplicates. Data plotted represent mean values and the
standard error of the mean (SEM); a non-linear regression line was generated using GraphPad Prism 5. Scale= 100 µm
Table 1 Antibody characteristics. VJ assignments, CDR3 sequences, % identity, and isotype for the antibody clones. IMGT/V-
QUEST software was used to assign the germline reference for IGHV and IGLV and determine % identity to germline. ELISAs
were done to determine reactivity and microneutralization assays were performed to determine neutralization activity at
concentrations up to 100 µg per mL
Antibody V-
Gene
J-
Gene
CDR3 %
Identity
Isotype V-
Gene
J-
Gene
CDR3 %
Identity
Isotype Reactivity to
PRVABC59
NS1
Reactivity
to MR766
NS1
Neutralization
activity (IC50)
AA12 VH3-
53
JH3-
02
CARDRRGFDYW 99% IgG1 VK1-
39
JK4-
01
CQQTYSTPLTF 98% Kappa Yes Yes None detected
FC12 VH3-
53
JH3-
02
CARGPVQLERRPLGAFDIW 99% IgG1 VL3-
1
JL2-
01
CQAWDSSTVVF 100% Lambda Yes No None detected
EB9 VH3-
53
JH3-
02
CARWGGKRGGAFDIW 100% IgG1 VK1-
39
JK2-
01
CQQSYSTPYTF 98% Kappa Yes Yes None detected
GB5 VH3-
53
JH3-
01
CARLIAAAGDYW 99% IgG1 VK1-
39
JK1-
01
CQQSYSTPWTF 98% Kappa Yes Yes None detected
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control (with no mAb added) groups correlated with each other
at around 14.06% for donor 1 and 22.6% for donor 2.
NS1 speciﬁc mAbs do not enhance ZIKV or DENV infection.
We next assessed whether NS1-speciﬁc mAbs were able to
enhance infection of target cells in vitro. ADE is commonly
observed when an antibody that opsonizes but does not fully
neutralize a virion facilitates infection of Fcγ-receptor bearing
target cells. We measured ADE using a ﬂow cytometry-based
assay in which serial dilutions of monoclonal antibody or serum
were mixed with PRVABC59 ZIKV and added to FcγR bearing
K562 cells, which are typically non-permissible to ZIKV infection.
After 48 h, cells were ﬁxed and stained for the envelope protein
using murine 4G2 antibody and the number of infected cells was
determined by ﬂow cytometry. We found that none of our NS1-
speciﬁc mAbs enhance Zika infection in vitro (Fig. 3). In contrast,
we observed a high level of ADE activity when K562 cells were
infected in the presence of DENV-immune plasma, indicating the
presence of cross-reactive antibodies between ZIKV and DENV
consistent with published literature14,35.
mAb AA12 protects against lethal heterologous challenges. To
assess the ability of NS1-speciﬁc mAbs to protect against ZIKV
disease in vivo, we performed lethal challenge experiments in a
mouse model. As Zika virus does not replicate in wild-type mice,
we used Stat2-/- mice which are permissive to Zika virus infection
and can display clinical signs of disease36. We administered
antibody AA12 intraperitoneally at 20 mg per kg two hours
before challenge. Irrelevant mAb at 20 mg per kg was used as an
isotype negative control. Mice were then infected with ten 50%
mouse lethal doses (10LD50) of the Zika virus strain MR766 and
weight loss, clinical scores, and survival were monitored daily.
Stat2-/- mice were bred in-house and colony sizes were a limiting
factor in the number of mice in each group to be tested. There-
fore, we performed murine challenge studies as two or three
independent replicates with at least three mice per treatment
group and data were then pooled. Mice that received 20 mg per kg
of AA12 showed minimal weight loss (Fig. 4a), signiﬁcantly
improved survival rate (Fig. 4b) and signiﬁcantly lower clinical
scores on 6 to 14 days post infection (dpi) (except 8 dpi) as
compared to the IgG control (Fig. 4c). Speciﬁcally, mice that
received 20 mg per kg of AA12 had an 83% survival rate while the
IgG control all succumbed to disease (0% survival). To determine
whether protection is relevant to the recent Zika virus outbreak or
limited to the mouse-adapted MR766 strain, we tested our mAbs
against a contemporary Panama 2015 strain (H/PAN/2015/CDC-
259359) from the Asian Zika virus lineage (Fig. 4d, e). We
challenged mice with the PAN/2015 isolate as this particular virus
demonstrated consistent mortality at the dose of 500 PFU in
Stat2-/- mice. In line with our previous data, AA12 was able to
signiﬁcantly protect animals from mortality at 10 mg per kg (63%
survival), while the IgG control was not (0% survival). AA12
trended towards higher protection in the Panama 2015 strain
challenge than the MR766 challenge likely due to the increased
neurovirulence of the mouse-adapted MR766 strain. We also
tested the two other monoclonal antibodies EB9 and FC12 in the
same passive transfer challenge using PAN/2015 (Supplementary
Figure 2). We show that EB9 protected 50% of the mice and FC12
only protected 25% of the mice compared to the IgG control
group. As we show that AA12 provided high levels of protection
against lethal challenge from both the historic African and more
modern Asian lineage of Zika viruses as shown in the survival
rates and disease clinical scores, this antibody was used for all
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Fig. 2 NS1-speciﬁc antibodies activate Fc-FcR effector functions in vitro. To examine the ability of NS1-speciﬁc antibodies to activate Fc-FcR mediated
effector functions, a, b Vero cells were infected with MR766 and PRVABC59 Zika viruses or c, d HEK 293T cells were transfected with NS1 from MR766
and PRVABC59 Zika viruses. Infected Vero cells or transfected HEK 293T cells were used as targets for measuring antibody-mediated effector functions
with a genetically modiﬁed Jurkat cell line expressing the human FcRγIIIa with an inducible luciferase reporter gene. Fold induction was measured in relative
light units and calculated by subtracting background signal from wells without effector cells then dividing wells with antibody by wells with no antibody
added. All mAbs were tested at a starting concentration of 10 μg per mL and were serially diluted four-fold. Assays were performed twice as technical
duplicates and one of two replicates is shown. A non-linear regression best-ﬁt curve was generated for each dataset using GraphPad Prism 5. Error bars
represent SEM
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future experiments. Additionally, viral burden was measured in
mice infected with PAN/2015 and treated with either 10 mg per
kg of AA12 or IgG control (Supplementary Figure 3). On days 3
and 6 post-infection, mice were euthanized and spleens and
brains were harvested and homogenized. Viral titers were then
determined by plaque assay. Interestingly, no virus was detected
in the brains of infected mice on day 3 post-challenge. However,
on day 6, virus was detected in the brains of all three mice
administered IgG control and only one of the three mice in the
AA12 treatment group. On day 3, there was a signiﬁcant
reduction of viral load in the spleens of AA12 administered
mice compared to the control group, while only one mouse given
AA12 had a detectable load of virus on day 6. Collectively, we
demonstrate that administration of AA12 can signiﬁcantly
improve survival rates against two ZIKV strains, prevent disease
severity and decrease viral titers in the spleens of mice.
NS1 mediated protection is Fc dependent. We next examined
whether Fc-FcγR or Fc-complement interactions are required for
providing protection in vivo. First, we cloned the heavy chain
variable regions of AA12 into expression vectors containing the
human IgG1 framework with the amino acid mutations L234A,
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Fig. 3 NS1-speciﬁc antibodies do not cause antibody-dependent enhancement (ADE) of infection in vitro. To examine whether enhancement of ﬂavivirus
infection in vitro is observed, ZIKV NS1-speciﬁc mAbs or pooled serum from a DENV positive donor were incubated with a PRVABC59 or b DENV-3
viruses and added to FcγR bearing K562 cells. All mAbs were tested at a starting concentration of 100 ng per mL and were serially diluted four-fold. DENV
positive control sera was diluted ﬁve-fold initially and serially diluted four-fold. The assay was run in duplicate and fold induction was measured as number
of infected cells as measured by ﬂow cytometry divided by infected cells with no antibody or serum added. Sera were obtained through a screening of
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Fig. 4 NS1-speciﬁc antibodies protect mice against lethal challenge in vivo. a–c Groups of 6–9 male and female B6.129-Stat2-/- mice were injected IP with
20mg per kg of AA12 before a challenge with 10 mLD50 of ZIKV MR766 intradermally. A mAb (CR9114) against inﬂuenza A virus was used as an IgG
control. d, e Mice were treated with 10mg per kg of AA12 or 10 mg per kg of isotype control before a challenge with 500 PFU of ZIKV PAN/2015 retro-
orbitally. Weight loss was monitored daily. For mice infected with ZIKV MR766, clinical scoring was conducted using the pre-deﬁned criteria with a
maximum possible score of 7: impact on walking (1), unresponsiveness (1), left hind leg paralyzed (1), right hind leg paralyzed (1), left front leg paralyzed
(1), and right front leg paralyzed (1). Deceased animals were awarded a score of 7. The ratios in the ﬁgures indicate the number of animals that survived
challenge over total number of animals per group. Murine challenge studies were performed as two independent replicates with at least three mice per
treatment group and data shown here were pooled. The Mantel-Cox and Gehan-Breslow-Wilcoxon tests were used to analyze statistical signiﬁcance of
survival between two groups. A multiple t-test and the Holm-Sidak method were used to determine statistical signiﬁcance at each time point for the weight
curve and the clinical score. Asterisk(s) indicates statistical signiﬁcance of a group (*p < 0.05 and **p < 0.005) compared to control IgG. No signiﬁcant
differences between groups were detected in d
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L235A, and P329G37–39. These mutations abolish the interaction
of the Fc region with Fcγ receptors and complement proteins. To
conﬁrm that the mutations do not interfere with antigen binding,
we tested both variants by ELISA (Fig. 5a, b). Both the WT and
mutated form of AA12 bound to the MR766 and PRVABC59
NS1 proteins identically. These variants were tested again in an
Fc-FcγR engagement assay, and, as expected, only the wild-type
AA12 variant showed activity (Fig. 5c, d).
We then examined if our AA12 variant has any protective
activity in vivo, by performing the same prophylactic passive
transfer challenge as done previously with ZIKV MR766. We
observed that while weight changes were not substantially
different from the different groups (Fig. 6a), administration of
wildtype AA12 (10 mg per kg) signiﬁcantly improved the survival
rate (~53%) and clinical score over mice receiving the AA12 with
ablated Fc-FcγR and complement interactions (LALAPG) or the
IgG control (Fig. 6b). Lastly, we demonstrate that Fc-FcγR or Fc-
complement interactions are required to prevent onset of severe
disease as wildtype AA12 can signiﬁcantly decrease the clinical
score (days 10–14) (Fig. 6c). Next, we tested the L234A, L235A
mutations or the P329G mutation alone by introducing the LALA
or PG point mutations into the AA12 antibody. Antibodies with
either of these mutations alone had comparable binding afﬁnity
with the wildtype, were inactive in the Fc-FcγR engagement assay
(Supplementary Figure 4) and were tested in a prophylactic
passive transfer challenge with ZIKV MR766. The AA12 LALA
was not protective and AA12 PG only protected 25% of mice. It is
possible that the single point mutation in PG did not completely
disrupt Fc-FcγR engagement and some Fc-FcγR effector func-
tions remained resulting in modest protection in our challenge
model. However, as shown in Fig. 6c, both AA12 LALA or AA12
PG failed to decrease onset of severe disease. Overall, our data
strengthens our previous ﬁndings that Fc-FcγR effector functions
remain critical in protection afforded by mAb AA12. We then
wanted to determine whether complement was activated during
infection by Zika virus. We tested whether treatment with the
AA12 variants ablated complement activation as compared to the
wild-type AA12. We measured complement in serum at day 6
post-infection by ELISA in four of the mice used in the challenge
from Fig. 6. We chose day 6 as mice typically begin to show
clinical signs of infection and high viral burden at this point. All
mice undergoing the challenge had higher levels of complement
activation as compared to naïve uninfected STAT2-/- mice
(Supplementary Figure 5). However, complement levels were
elevated most in infected mice receiving the IgG control. It is
therefore likely that these levels correlate most with morbidity
and are activated by increased viral replication and the resulting
heightened proinﬂammatory state. As wild-type AA12 protected
mice against challenge more effectively than AA12 LALA or
AA12 PG, it is unsurprising that complement levels were more
elevated in the latter two groups.
Discussion
Several other groups have isolated and characterized human
monoclonal antibodies to ZIKV8–12, however, the main focus of
these studies was on potently neutralizing antibodies targeting E,
the surface envelope glycoprotein present on the virion. While a
strong neutralizing antibody response to structural viral proteins
contributes to protection against infection and disease, less is
known about non-neutralizing antibodies that target the non-
structural proteins, such as NS1. Currently, there is a paucity of
data on the protective efﬁcacy of monoclonal antibodies that
target the Zika virus NS1 protein. As many candidate ﬂavivirus
vaccines omit the NS1 component40, it is possible that antibodies
targeting the NS1 are overlooked in the protective immune
response to ZIKV infection in humans. Of note, a recent study
highlights the importance of incorporating NS1 in a multivalent
vaccine against ZIKV41. Though Zika virus has one serotype with
regards to a neutralizing response42, less is known about whether
non-neutralizing antibodies against NS1 are able to target mul-
tiple strains of the virus. NS1 is highly conserved amongst Zika
virus strains, approaching 99.3% sequence identity43. The high
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level of conservation in NS1 proteins implies an immune
response targeting NS1 may protect against all circulating strains
and is a good candidate target for a vaccine. In fact, a recent study
demonstrated that a ZIKV NS1-based vaccine using a Modiﬁed
Vaccinia Ankara (MVA) vector is protective against a hetero-
logous ZIKV challenge in mice32. Notably, the vaccine was given
to wild-type mice who were subsequently challenged intracere-
brally. As passive transfer studies have not been conducted, it is
unclear which arm of the adaptive immune response, cell-
mediated or humoral antibody immunity, contributed most to
protection against disease. Our studies build on previous work
and indicate that NS1-speciﬁc mAbs contribute to protection and
should play in important role in the formulation of novel ﬂavi-
virus vaccines.
In the present study, we isolated plasmablasts from the PBMCs
of a ZIKV-infected individual around 15–20 days after infection.
Cloning of the variable regions of the antibody sequences isolated
from plasmablasts revealed four NS1-speciﬁc mAbs that can bind
to the recent Puerto Rico (PRVABC59) isolate of ZIKV. Inter-
estingly, only the antibody FC12 is unable to bind the historic
Uganda (MR766) strain of ZIKV, which has been isolated from
rhesus macaques in 1947 and subsequently passaged in mice.
While the ZIKV NS1 protein is highly conserved across many
strains, the ﬁnding that one (FC12) of four mAbs isolated
recognized only a recent ZIKV strain suggest that there may be
different immunodominant regions of NS1 that vary between
isolates. By isolating and characterizing more NS1-speciﬁc mAbs,
the antigenic regions of the NS1 protein can be mapped and used
for incorporating the NS1 protein in candidate ZIKV vaccines.
With biolayer interferometry, we show the afﬁnity of our anti-
bodies to be between 10-7 and 10-8 molar, which suggests a
moderate level of afﬁnity. However, the bivalent manner by which
NS1-speciﬁc mAbs bind to homodimeric NS1 suggest that avidity
may play a role in increasing their biological function in vivo.
Though the calculated afﬁnity is lower than many potently neu-
tralizing antibodies, it must be noted that these antibodies have
lower levels of somatic hypermutation. We speculate that we may
ﬁnd more NS1-speciﬁc antibodies with higher afﬁnities and levels
of somatic hypermutation in the memory B cell compartment of
the same individual or in individuals who have had repeated
exposures to the virus.
Vaccines that elicit NS1-speciﬁc mAbs do not risk inducing
antibody-dependent enhancement of disease (ADE). In contrast,
the recent Dengvaxia® vaccine, which induced antibodies to the
structural components of dengue virus, caused an increased risk
of severe disease in ﬂavivirus naïve children, resulting in the
suspension of the sale and distribution of the vaccine in the
Philippines44,45. To date, there are no clear cases involving ADE
induced by ZIKV infection in humans. However, passive transfer
of DENV or WNV immune plasma to immunocompromised
mice has resulted in more severe disease progression upon ZIKV
infection14. Additionally, ZIKV-induced monoclonal antibodies
can enhance infection of DENV in vitro8. This is a major concern
as ZIKV and dengue viruses are closely related, share the same
mosquito vector, and impact the same geographic regions. Our
studies suggest that as the NS1-speciﬁc mAbs are unable to
enhance viral uptake in vitro, an NS1-based vaccine will be a safer
alternative to current ﬂavivirus vaccine preparations.
Using a murine challenge model, we demonstrate that NS1-
speciﬁc mAbs can prevent death and disease in vivo. Our studies
use B6.129-Stat2-/- mice that are challenged intradermally with
MR766 or retro-orbitally with PAN/2015. Though the two ZIKV
sequences are highly conserved, the viruses were isolated 68 years
apart and display different phenotypes in mice. Therefore, both
strains were tested in our studies. Infection with the MR766 strain
represents a stringent challenge, inducing a higher level of
inﬂammatory cytokines and severe neurological symptoms when
mice are infected intradermally36. Mice infected with the Asian
lineage strain PAN/2015 were infected retro-orbitally to display
consistent lethality in our challenge models. We found that mAb
AA12 is able to signiﬁcantly improve the survival rates of mice at
doses of 20 mg per kg (83%) or 10 mg per kg (53%) during
MR766 challenge and at a dose of 10 mg per kg (63%) during
PAN/2015 challenge. Moreover, both doses of wildtype
AA12 signiﬁcantly decreased disease as measured by clinical
score. Treatment of AA12 was also found to greatly reduce viral
burden in the spleens of mice infected with PAN/2015 at day 3
post-infection. Moreover, we show that EB9 and FC12 trend
towards partial protection against the recent PAN/2015 isolate of
ZIKV at 10 mg per kg. Future experiments will determine the
optimal range by which full protection is achieved.
Fcγ-mediated protection induced by non-neutralizing or
poorly neutralizing antibodies has been found to play an
important role in the context of many other viral infections
including inﬂuenza A virus46–49, and it is unsurprising that these
functions may protect against Zika virus disease. To explore
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whether Fcγ-mediated immunity is required for protection
against ZIKV challenge, we cloned the heavy chain variable
region of AA12 into an expression plasmid with the mutations
L234A, L235A, and P329G in the Fc region37–39. These mutations
resulted in ablated Fcγ-effector functions as measured by a sur-
rogate reporter assay. The ﬁnding that the mutant AA12 mAb
(AA12-LALAPG) is unable to protect mice against lethal chal-
lenge suggest that activation of Fcγ-mediated effector functions is
the mechanism by which protection is achieved. Additionally,
AA12 antibodies with the L234A, L235A, or the P329G mutations
alone are also unable to protect mice against lethal challenge. To
determine whether complement plays a role in reduction of viral
burden, we measured C3 levels in mice undergoing lethal chal-
lenge. We found that C3 levels are elevated in mice treated with
AA12 LALAPG, AA12 PG, and IgG Control compared to mice
treated with wild-type AA12. As wild-type AA12 suppresses viral
burden and decreases disease severity, similar suppression of
complement activation is seen. However, as mutant antibodies are
unable to protect against lethal challenge, complement levels are
increased—likely correlating with increased levels of disease and
viral burden.
Notably, a high concentration of mAbs is required to confer
protection against lethal challenge. As these mAbs are non-
neutralizing and target a nonstructural protein, sterilizing
immunity is not achieved. Though NS1-speciﬁc antibodies may
not protect against initial infection, these antibodies limit disease
severity as measured by decreasing weight loss and clinical score
in antibody-treated animals. The induction of Fcγ-mediated
protection by NS1-speciﬁc antibodies may therefore be an over-
looked correlate of protection in the hunt for promising Zika
virus vaccines. A complete vaccine that elicits not only neu-
tralizing but also NS1-speciﬁc antibodies may increase protection
against Zika virus disease in humans.
A lack of established diagnostics also hampers ZIKV virus
vaccine development. Often, neutralizing antibody titers are used
as a readout if viral RNA levels are not detected. Testing serum by
plaque reduction neutralization tests may be additionally com-
plicated by high levels of dengue virus cross-reactive antibodies.
As the NS1 protein is highly conserved amongst ZIKV strains but
only exhibits 55% identity with dengue virus43, testing for NS1-
speciﬁc antibodies may lead to better ZIKV diagnostics. Recent
studies demonstrate a rapid NS1-based antigen test using
monoclonal antibodies50–52. We add to this work by reporting a
highly speciﬁc antibody (FC12) only able to recognize the more
recent ZIKV isolate. We suspect that this antibody may provide a
high-level of sensitivity and speciﬁcity in detecting serum levels of
ZIKV NS1 in patients infected by recent outbreaks.
It is also notable that all four NS1-speciﬁc antibodies isolated
from this patient had the same VH3−53/JH3 rearrangement but
with different light chains (Table 1). This same rearrangement
was found in NS1-speciﬁc antibodies isolated from two different
patients from a separate recent study53. Therefore, this rearran-
gement is found in many expanded B cell clones across the
human population that target Zika virus NS1. Further investi-
gation into how this germline rearrangement affects antibody
binding to NS1 is warranted. This is also the ﬁrst report of
recurring antibodies that share the same IGV genes in the context
of Zika virus NS1.
Teratogenic effects of ZIKV on the developing fetus in preg-
nant mothers is a major concern in the ongoing epidemic. In fact,
it was the causal relationship between ZIKV infection during
pregnancy and microcephaly that led the WHO to declare Zika
virus a “public health emergency of international concern”. In
light of our work, future studies should examine the prevention of
viremia and maternal-fetal transfer of virus by NS1-speciﬁc mAbs
or NS1-based vaccines.
In summary, our work helps to further dissect the components
of the antibody response against Zika virus. We have highlighted
the importance of mAbs targeting the NS1 protein which can
dramatically protect against disease and death in a murine chal-
lenge model. Furthermore, we demonstrate that NS1 antibody-
based protection against ZIKV disease is Fc-mediated. Lastly, the
lack of ADE induction as measured by an in vitro assay suggests
an NS1-based vaccine can reduce the risk of severe disease in
ﬂavivirus naïve patients as compared to a structural protein-based
vaccine.
Methods
Cells and viruses. Human embryonic kidney (HEK) 293T cells (American Type
Culture Collection; ATCC Cat. No. CRL-1573) and African green monkey kidney
cells (Vero; ATCC Cat. No. CCL-81) were grown in Dulbecco modiﬁed Eagle
medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS)
(Hyclone) and antibiotics (100 units per mL penicillin–100 µg per mL streptomycin
[Pen-Strep]; Gibco). Human embryonic kidney Expi293F cells (Gibco) were grown
in Expi293 expression media. MR766 virus (Rhesus/1947/Uganda BEI NR-50065),
PRVABC59 virus (2015/Puerto Rico; BEI NR-50684) and PAN/2015 virus (H/
PAN/2015/CDC-259359) were obtained from BEI resources. Fcγ-receptor
expressing K562 cells were obtained through ATCC (Cat. No. CCL-243). Pan-
ﬂavivirus antibody 4G2 was obtained through ATCC D1-4G2-4-15 (ATCC® HB-
112™). ZIKV were propagated in Vero cells in 1× Minimum Essential Medium
(MEM); after 72 h post-infection (hpi), cell culture supernatants were harvested,
aliquoted and stored at −80 °C until use.
Human plasmablast isolation. Plasmablasts were isolated at approximately two
weeks after onset of symptoms. Plasmablasts (CD19+/CD3-/CD20−/CD38high/
CD27high) were isolated and monoclonal antibodies were generated33 in accor-
dance with the Icahn School of Medicine at Mount Sinai Institutional Review
Board. Brieﬂy, Ficoll density (GE Healthcare) centrifugation was performed to
isolate the buffy coat, and peripheral blood mononuclear cells (PBMCs) were
single-cell sorted onto freshly made catch buffer (50 µL of 1 M Tris pH 8 and
125 µL of Rnasin in 5 mL of RNAse-free water) on 96-well plates using a BD
FACSARIA III. Reverse transcription reactions were performed to generate
cDNA33,34. Two nested PCRs incorporating IgG-speciﬁc, IgA-speciﬁc, IgM-spe-
ciﬁc, kappa-speciﬁc, and lambda-speciﬁc primers were performed on the cDNA to
amplify heavy and light chains. The International Immunogenetics Information
System software, (http://www.imgt.org/IMGT_vquest/vquest) was used to view
productive immunoglobulin sequence rearrangements. Sixteen Zika virus anti-
bodies were isolated from one patient, four of which are NS1-speciﬁc and further
characterized in this study. All four NS1-speciﬁc antibodies, AA12, EB9, FC12 and
GB5 have the VH3-53/JH3 heavy chain and are of the IgG1 isotype (Table 1).
Recombinant human antibodies. The human heavy (VH) and light (VL) variable
regions of the antibodies AA12, EB9, GB5, and FC12 were ampliﬁed by PCR and
cloned into human IgG1 and kappa or lambda mammalian expression vectors,
respectively (pFUESss-CHIg-hIgG1, pFUESss-CLIg-hK or pFUSEss-CLIg-hl2;
Invivogen). The L234A, L235A, and P329G (LALAPG) mutations in the IgG1
heavy chain were introduced by site-directed mutagenesis. The variable region of
the heavy chain of AA12 was then cloned into the modiﬁed expression vector to
make AA12-LALAPG. Wild-type or LALAPG antibodies (mutated IgG1 heavy
chain with wild-type kappa chain) were expressed and puriﬁed33.
Recombinant ZIKV NS1. The NS1 gene segments from MR766 virus (Rhesus/
1947/Uganda Accession: NC_012432) and PRVABC59 virus (2015/Puerto Rico
Accession: KU501215) were human codon optimized using Integrated DNA
Technologies Codon Optimization Tool (http://www.idtdna.com/CodonOpt) and
modiﬁed to contain a C-terminal hexahistidine-tag. NS1 gene segments were
subcloned into the expression plasmid pCAGGS using restriction endonucleases
NotI and XhoI (New England Biosciences) and inserted into the digested plasmid
by homologous recombination (In-Fusion, Takara) to construct pCAGGS-MR766-
NS1 and pCAGGS-PRVABC59-NS1. To generate recombinant NS1 proteins, 30
mL of Expi293 cells were transfected with 30 µg of pCAGGS-MR766-NS1 or
pCAGGS-PRVABC59-NS1 plasmids and 81 µL of expifectamine reagent as per
manufacturer’s instructions. After 120 h, supernatants were cleared by low-speed
centrifugation and incubated with Ni-NTA resin overnight at 4 ˚C. The resin-
supernatant mixture was then passed over 10 mL polypropylene columns (Qiagen).
The retained resin was washed four times with 15 mL of washing buffer (50 mM
Na2HCO3, 300 mM NaCl, 20 mM imidazole, pH 8) and protein was eluted with
elution buffer (50 mM Na2HCO3, 300 mM NaCl, 300 mM imidazole, pH 8). The
eluate was concentrated using Amicon Ultracell (Millipore) centrifugation units
with a cut-off of 10 kDa and buffer was changed to phosphate buffered saline (PBS)
of pH 7.4. Protein concentration was quantiﬁed using Pierce Bicinchoninic Acid
Protein Assay Kit (Thermo Scientiﬁc) with a bovine serum albumin standard
curve. Puriﬁed soluble NS1 proteins were resolved in a reducing and denatured
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SDS-PAGE gel (in monomeric forms of around 45 kDa and homodimeric forms of
around 90 kDa) and visualized using SimplyBlue SafeStain (Thermoﬁsher, Inc.).
Enzyme-linked immunosorbent assay. Plates were coated with recombinant
ZIKV NS1 at 2 μg per mL in pH 9.41 carbonate buffer overnight at 4 ˚C. After
blocking in 5% non-fat (NF) milk for 1 h, mAbs were incubated at a starting
concentration of 10 μg per mL and serially diluted 3-fold and incubated 2 h at room
temperature. Horseradish peroxidase (HRP)-conjugated goat anti-human IgG
antibody (AP504P; Millipore Sigma) was used to detect binding of the mAbs,
followed by development with HRP substrate (Sigmafast OPD; Sigma-Aldrich).
Reactions were stopped by addition of 3M HCl and absorbance was measured at
490 nm on a microplate spectrophotometer (BioRad). Experiments were performed
in duplicates and repeated twice. Graphpad Prism 5 was used to visualized the
mean values and the standard error of the mean (SEM) and generate a non-linear
regression curve.
Immunoﬂuorescence. Vero cells were infected with ZIKV MR766, ZIKV
PRVABC59 or dengue virus type 3, Philippines/H87/1956 with a multiplicity of
infection (MOI) of 1. After 24 h post-infection, the monolayer of Vero cells was
ﬁxed with 0.5% of paraformaldehyde (PFA)/1× PBS. Cells were blocked with 5%
nonfat milk for 30 min at room temperature. Blocking buffer was then discarded
and NS1-speciﬁc mAbs were added at a concentration of 5 µg/mL in nonfat milk.
Primary antibodies were incubated for 2 h at room temperature after which the
monolayer was washed three times with 1× PBS. An anti-human or anti-mouse
IgG secondary antibody conjugated to Alexa Fluor 488 (ThermoFisher) diluted
(1:000) in nonfat milk was added to the monolayer and incubated in the dark at RT
for 1 h. The monolayer was then washed three times with 1× PBS. Cells were then
visualized using an inverted ﬂuorescent microscope (Olympus IX70).
Microneutralization assay. To assess the in vitro neutralizing activity of the mAbs
we performed a microneutralization (MN) assay. Three-fold serially diluted anti-
body (starting at 100 μg per mL) in serum-free minimum essential medium (MEM)
was mixed with an equal volume of virus (100 TCID50) and incubated for 1 h at
room temperature. Monolayers of Vero cells were washed once with PBS and the
virus/antibody mixture was added to the cells and incubated for 1 h at 37 ˚C. After
the infection, the virus/antibody mixture was removed and replaced with serum-
free MEM with antibody added at the appropriate dilution. The cells were then
incubated at 37˚C for 72 h. Cytopathic effect (CPE) was scored at three days post
infection and IC50 was quantiﬁed by the Reed and Muench method.
Antibody dependent effector functions. For experiments involving infected cells,
Vero cells were seeded on 96-well ﬂat white-bottom plates (Corning) and infected
after 24 h with ZIKV (MR766 or PRVABC59) at an MOI of 0.01. For experiments
involving transfected cells, HEK 293T cells were seeded onto poly-D-lysine coated
96-well ﬂat white-bottom plates (Corning). After 24 h, the cells were transfected
with 100 ng per well of expression plasmid encoding NS1 from MR766 or
PRVABC59. At 16 h post-transfection or 40 h post-infection, the medium was
removed and 25 μL of assay buffer (RPMI 1640 with 4% low-IgG FBS) was added
to each well. Then mAbs were added in a volume of 25 μL at 30 μg per mL and
serially diluted fourfold in assay buffer (in duplicate). The mAbs were then incu-
bated with the transfected or infected cells for 30 min at 37 ˚C. Genetically mod-
iﬁed Jurkat cells expressing the human FcγRIIIa with a luciferase reporter gene
under the transcriptional control of nuclear factor-activated T cells (NFAT) pro-
moter were added at 7.5 × 104 cells at 25 μL per well, which is approximately a 1:2
ratio of target cells to effector cells, followed by incubation for another 6 h at 37 ˚C
(Promega). Bio-Glo Luciferase assay reagent was added after 6 h and luminescence
was quantiﬁed using a plate reader. Fold induction was measured in relative light
units and calculated by subtracting background signal from wells without effector
cells then dividing wells with antibody by with no antibody added. Speciﬁcally, fold
induction was calculated as follows: (RLUinduced – RLUbackground)/(RLUuninduced –
RLUbackground). The mean values and SEM were reported and a nonlinear regres-
sion curve was generated using GraphPad Prism 5.
Alternatively, we measured antibody-dependent effector functions by detecting
activation of primary human natural killer (NK) cells (expression of CD107a) as
previously described47. Brieﬂy, Vero cells were seeded at 2 × 104 cells per well in
96-well cell culture-treated plates and infected with PRVABC59 ZIKV with an
MOI of 0.5 (adjusted for cell growth overnight). At 48 hpi, growth media from
infected Vero cells were aspirated and incubated with dilutions (50 µL total
volume) of NS1-speciﬁc mAbs (diluted in 1× Iscove’s media supplemented with
10% FBS) starting at 20 µg per mL, serially diluted 3-fold and incubated at 37 °C,
CO2 for 1.5 h. A human mAb speciﬁc for the inﬂuenza B virus hemagglutinin,
II2C7, was used as an irrelevant mAb and a group containing no mAb was used as
background control. Human NK cells were isolated (Lymphoprep; Stemcell
Technologies, Inc.) from buffy coat donors (San Diego Blood Center) through
negative selection (EasySep Human NK cell isolation kit; Stemcell Technologies,
Inc.) and 8 × 105 CD56+ cells/well (in 50 µL 1× Iscoves’s media supplemented with
10% FBS; effector cells to target ratio of 2) were subsequently added to the ZIKV-
infected Vero cells and mAb mixture (total volume of 100 µL). Cells were incubated
for 3 h at 37 °C, CO2. Cells were then washed with wash buffer (1X PBS/1% BSA)
and stained with CD56-FITC (Clone B159 BD Biosciences; 5 µL per 1e6 cells) and
CD107a-PE (Clone H4A3 BD Biosciences; 20 µL per 1e6 cells) for 15 min at 4 °C
(in the dark). Samples were then resolved in a BD FACS ARIA II ﬂow cytometer
sorter (BD Biosciences) and analyzed using FlowJo 10.5.0. Experiments were
performed in duplicates and the means/standard error were graphed using
GraphPad Prism 5.
KD determination. Biolayer interferometry assays were performed with an Octet
RED instrument (ForteBio, Inc.) to determine KD values. Puriﬁed recombinant
NS1 was loaded onto a Ni-NTA biosensor (ForteBio, Inc.) in kinetics buffer (1×
PBS pH 7.4, 0.01% BSA, 0.002% Tween-20) for 3 min. To determine kon, asso-
ciation was measured for 3 min by exposing the sensors to seven concentrations of
antibody diluted in kinetics buffer. To determine koff, dissociation was measured
for 3 min in kinetics buffer. KD values were calculated as the ratios of koff to kon. We
used a 2:1 binding model to reﬂect two identical binding sites of homodimeric NS1
proteins. K1 and K2 reﬂect the kinetics constants of the ﬁrst and seconding binding
interaction between the mAb and a homodimeric NS1.
Antibody dependent enhancement of infection. Enhancement of ZIKV or
DENV infection was measured using a ﬂow-cytometry-based assay14. Serial dilu-
tions of puriﬁed monoclonal antibody were mixed with ZIKV (PRVABC59 MOI of
1) for 1 h at 37 ˚C in RPMI 1640 media supplemented with 10% FBS, 2 mM L-
glutamine, and antibiotics (100 units per mL penicillin–100 µg per mL strepto-
mycin [Pen-Strep]; Gibco). The mixture was then added to K562 cells in 96-well U
bottom plates. After two days, cells were ﬁxed with 4% PFA/1X PBS, permeabilized
with PBS containing 0.2% BSA and 0.05% saponin and stained with 4G2 pan-
ﬂavivirus anti-envelope antibody (1 μg per mL) for 1 h at RT. Cells were then
incubated with goat anti-mouse IgG conjugated to phycoerythrin (1 μg per mL;
Invitrogen) for 1 h at RT. The number of infected cells was determined by ﬂow
cytometry using a FACS Caliber and analyzed using FlowJo2 software version 10.1.
r7. Area under the curve was calculated using GraphPad Prism.
Passive transfer studies. All animal experiments were performed in an animal
biosafety level 2 plus facility in accordance with the Icahn School of Medicine at
Mount Sinai and the University of California, Riverside Institutional Animal Care
and Use Committees (IACUC). Groups of 5–9 male and female B6.129-Stat2-/-
mice (kindly provided by Dr. Christian Schindler) were passively transferred with
20 or 10 mg per kg AA12, or 10 mg per kg AA12-LALA, AA12-PG or AA12-
LALAPG antibody intraperitoneally. Control mice received the human anti-
inﬂuenza antibody CR911454 at a dose of 10 mg per kg. Mice were challenged
intradermally with 10 LD50 ZIKV MR766 or retro-orbitally with 500 PFU of ZIKV
PAN/2015 and evaluated for 14 days. Mice were monitored daily for weight and
clinical signs. Clinical scoring was conducted using the pre-deﬁned criteria with a
maximum possible score of 7: impact on walking, unresponsiveness, left hind leg
paralyzed, right hind leg paralyzed, left front leg paralyzed, and right front leg
paralyzed. Deceased animals were given a score of 714,55. Animals that showed
more than 25% weight loss or full paralysis were humanely euthanized. Experi-
ments were conducted with a balanced amount of male and female mice and with
an even distribution of mice from different litters whenever possible. To determine
statistical signiﬁcance, the Mantel-Cox and Gehan-Breslow-Wilcoxon tests were
used for survival curves and a multiple t-test and the Holm-Sidak method utilized
to analyze the weight curve and clinical scores. Asterisk(s) on graphs indicates
statistical signiﬁcance (*p value < 0.05 and **p value < 0.005) of a group compared
to the IgG control group.
Viral titers. Tissue samples were harvested from infected mice, placed in PBS, and
homogenized using ceramic beads. ZIKV quantiﬁcation was conducted via plaque
assay. Brieﬂy, Vero cells were plated in 24-well plates and infected after 24 h with
dilutions of virus made in serum-free 1× MEM medium. Infectious medium was
aspirated and 600 μL of methylcellulose agar equivalent medium was added to each
well. At day 4 post-infection plates were ﬁxed with 4% PFA for 1 h at RT, washed,
and stained with 4G2 in milk at 5 μg per mL. Secondary anti-mouse HRP was then
added at 1:5000 in milk and the assay was resolved with TrueBlue Peroxidase
Substrate (VWR). Plaques were manually counted and plaque forming units (PFU)
per mL of homogenized tissue was calculated.
Complement ELISA. A mouse complement C3 ELISA kit (Abcam: ab157711) was
used as per the manufacturer’s instructions to measure C3 levels in the serum of
infected or naïve mice. Brieﬂy, serum was diluted 1:50,000 and pipetted into
designated wells. In parallel, a standard curve was generated from known con-
centrations of C3. The plate was incubated for 20 min, washed, and a 1× enzyme-
antibody conjugate was added. After incubation for twenty minutes and additional
washing, TMB substrate was added and absorbance was measured at 450 nm on a
microplate spectrophotometer (BioRad).
Study approval. An IRB approved written informed consent was obtained from
the patient prior to study participation. No further demographic data are included
here in order to protect the participant’s privacy.
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Statistical analysis. Results from multiple experiments are presented as mean ±
SEM. Student’s t-tests were used to test for statistical differences between mean
values. Data were analyzed with GraphPad Prism 7 software and p-values of <0.05
were considered statistically signiﬁcant.
Data availability
The sequences of the immunoglobulin variable regions for AA12 (VH accession
no. MH931170; VL accession no. MH931171), EB9 (VH accession no. MH931172;
VL accession no. MH931173), GB5 (VH accession no. MH931174; VL accession
no. MH931175), and FC12 (VH accession no. MH931176; VL accession no.
MH931177) have been deposited in GenBank. The authors declare that all other
data supporting the ﬁndings of this study are available within the article and its
Supplementary Information ﬁles, or are available from the authors upon request.
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